AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Korro Bio, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00GFMTC47
11.98▼ 0.07 (-0.58%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
12.05
Day's Range
11.28 – 12.49
52-Week Range
5.20 – 42.93
Volume
237.2K
Avg Volume
219.9K
Share Statistics
Shares Outstanding
Employees
58
Exchange
XNAS
Listed
2023-11-06
Share count as of August 5, 2026

Korro Bio, Inc. Common Stock (KRRO) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Korro Bio, Inc. Common Stock (KRRO)
What is Korro Bio, Inc. Common Stock's Market Cap?
Korro Bio, Inc. Common Stock's Market Cap is $176.4M, based on as-reported figures from SEC (XBRL) filings.
What is Korro Bio, Inc. Common Stock's Price / Sales?
Korro Bio, Inc. Common Stock's Price / Sales is 74.1×, based on as-reported figures from SEC (XBRL) filings.
What is Korro Bio, Inc. Common Stock's Revenue (TTM)?
Korro Bio, Inc. Common Stock's Revenue (TTM) is $2.4M, based on as-reported figures from SEC (XBRL) filings.
What is Korro Bio, Inc. Common Stock's Net Income (TTM)?
Korro Bio, Inc. Common Stock's Net Income (TTM) is -$106.6M, based on as-reported figures from SEC (XBRL) filings.
What is Korro Bio, Inc. Common Stock's EBITDA?
Korro Bio, Inc. Common Stock's EBITDA is -$107.6M, based on as-reported figures from SEC (XBRL) filings.
What is Korro Bio, Inc. Common Stock's Diluted EPS (TTM)?
Korro Bio, Inc. Common Stock's Diluted EPS (TTM) is -7.24, based on as-reported figures from SEC (XBRL) filings.
What is Korro Bio, Inc. Common Stock's EBITDA Margin?
Korro Bio, Inc. Common Stock's EBITDA Margin is -4517.5%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · KRROAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Collaboration revenue
YoY growth-100.0%-100.0%-43.1%—
Operating expenses:
Research and development
General and administrative
Restructuring charges———
Total operating expenses
% of revenue——4000.6%1864.9%
Loss from operations
% of revenue——-3900.6%-1764.9%
Other income:
Other income, net
Total other income, net
Loss before provision for income taxes
Provision for income taxes
Net loss
% of revenue——-3873.2%-1657.0%
Net loss per share, basic
Net loss per share, diluted